Skip to main content
. 2022 Jan 25;22(5):636–648. doi: 10.1016/S1473-3099(21)00764-7

Figure 1.

Figure 1

Trial profile up to study day 43

CMIAS=cell-mediated immunity analysis set. FAS=full analysis set. SafAS=safety analysis set. PPAS=per-protocol analysis set. No participants discontinued because of an adverse event. † One participant randomly assigned to the high-dose group received medium antigen-dose vaccine formulation on day 0 and received a high-dose formulation as planned on day 22.